Main characteristics of subjects included in the analysis
| Subjects' characteristics . | Value∗ . |
|---|---|
| HCWs | 82 |
| Men | 21 (25.6%) |
| Women | 61 (74.4%) |
| Age, y | 45.0 (35.0-53.0) |
| SARS-CoV-2 | |
| Naïve | 82 (100%) |
| Previously infected | — |
| TDT patients | 154 |
| Men | 61 (39.6%) |
| Women | 93 (60.4%) |
| Age, y | 44.0 (37.0-51.0) |
| Splenectomized | 83 (53.9%) |
| ICT | 154 |
| DFX | 80 (51.9%) |
| DFP | 20 (13.0%) |
| DFO | 18 (11.7%) |
| Combined | 31 (20.1%) |
| Not available | 5 (3.2%) |
| HU | 17 (11.0%) |
| SARS-CoV-2 | |
| Naïve | 132 (85.7%) |
| Previously infected | 22 (14.3%) |
| Subjects' characteristics . | Value∗ . |
|---|---|
| HCWs | 82 |
| Men | 21 (25.6%) |
| Women | 61 (74.4%) |
| Age, y | 45.0 (35.0-53.0) |
| SARS-CoV-2 | |
| Naïve | 82 (100%) |
| Previously infected | — |
| TDT patients | 154 |
| Men | 61 (39.6%) |
| Women | 93 (60.4%) |
| Age, y | 44.0 (37.0-51.0) |
| Splenectomized | 83 (53.9%) |
| ICT | 154 |
| DFX | 80 (51.9%) |
| DFP | 20 (13.0%) |
| DFO | 18 (11.7%) |
| Combined | 31 (20.1%) |
| Not available | 5 (3.2%) |
| HU | 17 (11.0%) |
| SARS-CoV-2 | |
| Naïve | 132 (85.7%) |
| Previously infected | 22 (14.3%) |
DFO, deferoxamine; DFP, deferiprone; DFX, deferasirox; HCWs, healthcare workers; HU, hydroxyurea; ICT, iron chelation therapy; TDT, transfusion-dependent β-thalassemia.
Values are n, n (%), or median (interquartile range).